|Day Low/High||297.86 / 304.80|
|52 Wk Low/High||215.78 / 374.99|
Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."
The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
The S&P 500 and Nasdaq end at records.
These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...
Stocks creep lower on Friday as a selloff in health care extends into its second day, this time led by Amgen shares.
Many want to undo what's been done, but not enough to send the market down.
Stocks give back earlier gains as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.
There are nearly too many surging sectors to count.
Jim Cramer compares Allergan's growth to other pharma stocks.
The Fed is simply not a market catalyst this time.
There are several reasons why Celgene should buy Biogen.
Shares of Biogen were lower Tuesday after the company resolved a dispute with Forward Pharma over its multiple sclerosis drug.